Hello. At which development phase of your drug are you? When do you plan commercialization? Thank you.

Hello Lea and thank you for your question. We are in the "Preclinical" stage of development. Our objective is to advance Corvida™'s development through Phase 1 and Phase 2 human trials, which will take 4-5 years. At this point we plan to sell or license Corvida™ to a large pharmaceutical company. They will conduct the Phase 3 trials and commercialize the product, which may take an additional 3 - 5 years.

Dear team of Corvidane, kindly let me know if the money raised so far from different sources will be enough to complete the preclinical phase? In addition, I would like to ask if you are going to pursue more crowdfunding or other sources to initiate and complete the clinical t...

Alexandros: My sincere apology for the late response and thank you for your question. Our target to complete the PreClinical phase is $2.5M USD. We are actively pursuing other funding sources including Venture capital on non-dilutive sources such as grants and subsidies to complete the preclinical phase and Phase 1 studies. Let me know if you have any other questions. Damion.

Any updates since the last raise?

Tal, I hope you are well. Your timing is great as Paresh will be sending an update within the next week. We look forward to sharing the update and some new developments with you and our investor community! Damion.

Corvidane

Developing a novel, safe drug to prevent heart attacks, strokes, and liver transplants.

Pitch Video

Investor Panel

corvidane.com

New York, NY

Minority Founder Biotech

Investor Panel

Jacob interviewed Corvidane on December 2, 2021. Play Video

Jacob Brutman

Angel Investor, Ph.D. Chemist and Computer Enthusiast

Strengths

says, "The molecules they are using are widely available and easy to produce, thus, they should not have a problem providing product. FDA approval can be a nightmare, but they seem to have a good grasp on what is required."

Advice

says, "If it does not already, ensure that your IP protects the company from competitors making slight modifications and then selling a similar product OTC. Whether it works as well or not, it would be sure to undercut your market."

What Investors Say

LEAD INVESTOR

Invested $2,000 this round + $26,000 previously

I invested in Corvidane and agreed to be the lead investor because of the leadership’s ambitious mission to develop a novel, safe drug to prevent heart attacks, strokes, and liver transplants from NASH, with a high chance of success because of the solid scientific rationale behind the product in these indications with an unmet medical need. A second very important reason for my interest in contributing to Corvidane is that the leadership team has strong domain expertise and previous operating experience. I expect this to lead to a better treatment for patients and financial benefits for investors.

Corvidane

Quick facts

Team profiles

Featured investor profiles

$366,884

Investor Panel

What Investors Say